Inside Gene Solutions’ ESMO 2026 Symposium and Scientific Program: Six Perspectives Across the Cancer Care Continuum

Panel Discussion​ | Bridging Regional Evidence to Global Precision Oncology: Challenges and Opportunities in Multi-Omic Liquid Biopsy Implementation Across the Cancer Care Continuum ESMO 2026 Gene Solutions

At ESMO Congress 2026 in Madrid, Gene Solutions hosted its first Industry Satellite Symposium at the main ESMO Congress, bringing clinical validation, real-world experience, and multi-omic innovation generated in Asia into the global oncology conversation. 

The full-house symposium, “AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation,” brought together six international faculty members to share scientific and clinical perspectives on the future of cancer detection and precision oncology. 

Co-chaired by Prof. Umberto Malapelle of the University of Naples Federico II and Prof. Herbert Ho Fung Loong of The Chinese University of Hong Kong, the program presented a connected, patient-centered scientific journey spanning multi-cancer detection, tissue and liquid-biopsy genomic profiling, molecular monitoring, immunogenetic discovery, and patient-derived 3D tumor organoids. 

Rather than viewing these technologies independently, the symposium explored how complementary molecular, biological, longitudinal, and functional information may work together across the cancer care continuum. 

Watch the symposium presentations 

Access the six faculty presentations and explore the key scientific messages from each session on the K-CONNECT platform. 

Prof. Umberto Malapelle 

Clinical Challenges with Multi-Cancer Early Detection Tests: Unmet Needs and Lessons for Next-Generation Approaches in Precision Oncology 

Explore the analytical, clinical, and implementation challenges shaping multi-cancer screening, including the evidence needed to support responsible clinical adoption. 

Prof. Umberto Malapelle Clinical Challenges with Multi-Cancer Early Detection Tests: Unmet Needs and Lessons for Next-Generation Approaches in Precision Oncology ESMO 2026 Gene Solutions

Watch Prof. Umberto Malapelle’s presentation on K-CONNECT

 

Dr. Le Son Tran 

AI-Enabled Multi-omic Cell-Free DNA Profiling for Multi-Cancer Detection: Technology Challenges, Large Validation Datasets and Pathways to Global and Diverse Implementation 

Explore how AI-enabled multi-omic cfDNA profiling was developed and evaluated through retrospective, prospective, and large-scale real-world datasets. 

Dr. Le Son Tran ESMO 2026 Gene Solutions AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation Multi-Omic Liquid Biopsy Approaches in Precision Oncology: Asian Real-World Evidence on Scale, Affordability and High-Precision Applications ESMO 2026 Gene Solutions

Watch Dr. Le Son Tran’s presentation on K-CONNECT 

 

Prof. Herbert Ho Fung Loong 

Multi-Omic Liquid Biopsy Approaches in Precision Oncology: Asian Real-World Evidence on Scale, Affordability and High-Precision Applications 

Explore how tissue and liquid biopsy can provide complementary molecular information across genomic profiling, treatment-response assessment, and longitudinal disease monitoring. 

Prof. Herbert Ho Fung Loong ESMO 2026 Gene Solutions AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation Multi-Omic Liquid Biopsy Approaches in Precision Oncology: Asian Real-World Evidence on Scale, Affordability and High-Precision Applications ESMO 2026 Gene Solutions

Watch Prof. Herbert Ho Fung Loong’s presentation on K-CONNECT 

 

Prof. Aya El Helali 

The Role of Multi-Omic Signals for Next-Generation Precision Oncology and Immunogenetic Discovery 

Explore how multi-omic information can deepen understanding of tumor biology, the immune microenvironment, neoantigen patterns, and therapeutic hypotheses. 

Prof. Aya El Helali The Role of Multi-Omic Signals for Next-Generation Precision Oncology and Immunogenetic Discovery Gene Solutions ESMO 2026 Prof. Aya El-Helali

Watch Prof. Aya El Helali’s presentation on K-CONNECT

 

Dr. Vien Le 

3D Patient-Derived Organoids in Precision Medicine: From Bench to Bedside 

Explore how patient-derived tumor organoids may add a functional research layer to genomic profiling and how prospective studies are evaluating their concordance with clinical treatment response.  

Dr. Vien Le Gene Solutions ESMO 2026 AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation

Watch Dr. Vien Le’s presentation on K-CONNECT 

 

Asst. Prof. Lucksamon Thamlikitkul 

ctDNA Monitoring in Early-Stage NSCLC: A Real-World Case Experience 

Explore a real-world lung cancer case illustrating how longitudinal ctDNA monitoring can complement imaging and tissue profiling, while highlighting the importance of interpreting molecular signals within the patient’s complete clinical history.  

Asst. Prof. Lucksamon Thamlikitkul Gene Solutions ESMO 2026 AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation

Watch Asst. Prof. Lucksamon Thamlikitkul’s case presentation on K-CONNECT 

 

Watch the panel discussion 

The symposium concluded with a multidisciplinary discussion on the clinical evidence, infrastructure, access, and implementation pathways required to translate innovation generated across different regions into globally relevant precision oncology. 

Watch “Bridging Regional Evidence to Global Precision Oncology: Challenges and Opportunities in Multi-omic Liquid Biopsy Implementation Across the Cancer Care Continuum” 

Hear directly from the faculty 

Following the symposium, participating faculty reflected on the scientific discussions, the evolving role of multi-omics, and the steps needed to translate advanced molecular technologies into meaningful and accessible cancer care.

Watch the ESMO 2026 faculty interviews

 

Explore Gene Solutions’ scientific posters 

Gene Solutions, in collaboration with the Medical Genetics Institute, also contributed scientific posters featuring real-world molecular profiling and ctDNA monitoring research from Southeast Asia. 

The studies explored how complementary tissue and liquid-biopsy approaches may support more comprehensive molecular profiling and longitudinal disease monitoring across multiple cancer types.  

Explore Gene Solutions’ scientific posters

An integrated vision for precision oncology 

Across the programme, one shared direction emerged: the future of precision oncology will require more than any single test or technology. 

Gene Solutions presented a patient-centered ecosystem that connects earlier detection, comprehensive genomic profiling, deeper biological and immune understanding, functional investigation of treatment response, and longitudinal ctDNA monitoring around the needs of the same patient. 

The next step is to continue expanding prospective clinical validation, strengthening international research collaborations, and generating the evidence needed to translate this integrated approach across diverse healthcare settings. 

This non-promotional medical educational symposium was organized and funded by Gene Solutions for healthcare professionals only.

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More